Log in

NYSE:QGENQiagen Stock Price, Forecast & News

-0.52 (-1.05 %)
(As of 08/3/2020 04:00 PM ET)
Today's Range
Now: $48.93
50-Day Range
MA: $45.39
52-Week Range
Now: $48.93
Volume1.36 million shs
Average Volume1.49 million shs
Market Capitalization$11.14 billion
P/E RatioN/A
Dividend YieldN/A
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, an application for analysis and interpretation of human sequencing data generated with next-generation sequencing (NGS) technologies; QIAGEN Clinical Insight, an evidence-based variant classification; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and order bioinformatics solutions and linking biological interpretation from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; QIAsymphony SP for sample preparation; QIAsymphony AS for assay setup; Rotor-Gene Q, a rotary real-time PCR cycler system; QIAstat-Dx for molecular analysis of common syndromes; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; NeuMoDx 288 and NeuMoDx 96 for automation of higher-throughput PCR testing in clinical laboratories; and QIAcube and QIAcube connect workstations, which provides versatile solutions for automated sample processing; It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has collaboration agreements with Ares Genetics and Laboratory Corporation of America Holdings. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Read More
Qiagen logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.85 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic



Sales & Book Value

Annual Sales$1.53 billion
Cash Flow$2.63 per share
Book Value$11.14 per share


Net Income$-41,460,000.00


Market Cap$11.14 billion
Next Earnings Date8/4/2020 (Confirmed)
-0.52 (-1.05 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive QGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Qiagen (NYSE:QGEN) Frequently Asked Questions

How has Qiagen's stock been impacted by COVID-19 (Coronavirus)?

Qiagen's stock was trading at $41.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, QGEN shares have increased by 19.1% and is now trading at $48.93.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Qiagen?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 1 sell rating, 14 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Qiagen

When is Qiagen's next earnings date?

Qiagen is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020.
View our earnings forecast for Qiagen

How were Qiagen's earnings last quarter?

Qiagen NV (NYSE:QGEN) posted its quarterly earnings results on Wednesday, May, 6th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. The firm earned $372.10 million during the quarter, compared to the consensus estimate of $342.71 million. Qiagen had a negative net margin of 2.01% and a positive return on equity of 13.80%. The business's revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.27 EPS.
View Qiagen's earnings history

What guidance has Qiagen issued on next quarter's earnings?

Qiagen updated its second quarter 2020 IntraDay earnings guidance on Monday, July, 13th. The company provided EPS guidance of 0.56-0.56 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.42. The company issued revenue guidance of $443-443 million, compared to the consensus revenue estimate of $417.3 million.

What price target have analysts set for QGEN?

18 analysts have issued 1-year price targets for Qiagen's stock. Their forecasts range from $28.00 to $48.00. On average, they expect Qiagen's share price to reach $36.73 in the next twelve months. This suggests that the stock has a possible downside of 24.9%.
View analysts' price targets for Qiagen

Has Qiagen been receiving favorable news coverage?

Media headlines about QGEN stock have trended somewhat negative on Tuesday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Qiagen earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future.
View the latest news about Qiagen

Are investors shorting Qiagen?

Qiagen saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 3,830,000 shares, an increase of 15.0% from the June 30th total of 3,330,000 shares. Based on an average daily volume of 1,130,000 shares, the days-to-cover ratio is presently 3.4 days. Currently, 1.7% of the shares of the company are short sold.
View Qiagen's Current Options Chain

Who are some of Qiagen's key competitors?

What other stocks do shareholders of Qiagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Netflix (NFLX), Pfizer (PFE), Twitter (TWTR), Micron Technology (MU), Paypal (PYPL), QUALCOMM (QCOM), Boeing (BA) and Alibaba Group (BABA).

Who are Qiagen's key executives?

Qiagen's management team includes the following people:
  • Mr. Peer Michael Schatz, CEO, MD & Member of Management Board (Age 53)
  • Dr. Roland Sackers, CFO, MD & Member of Management Board (Age 50)
  • Dr. Barthold Piening, Sr. VP & Head of Global Operations (Age 61)
  • Mr. John Gilardi, VP of Corp. Communications & Investor Relations
  • Mr. Jean-Pascal Viola, Head of Corp. Bus. Devel., Intellectual Property & Litigation and Sr. VP

What is Qiagen's stock symbol?

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

Who are Qiagen's major shareholders?

Qiagen's stock is owned by many different institutional and retail investors. Top institutional investors include ARP Americas LP (0.94%), First Trust Advisors LP (0.71%), Frontier Capital Management Co. LLC (0.05%), Raymond James & Associates (0.04%), Strs Ohio (0.02%) and Stone Ridge Asset Management LLC (0.02%).

Which institutional investors are selling Qiagen stock?

QGEN stock was sold by a variety of institutional investors in the last quarter, including Brinker Capital Inc., Frontier Capital Management Co. LLC, Nisa Investment Advisors LLC, Envestnet Asset Management Inc., Raymond James & Associates, Stone Ridge Asset Management LLC, and Coastal Investment Advisors Inc..

Which institutional investors are buying Qiagen stock?

QGEN stock was purchased by a variety of institutional investors in the last quarter, including ARP Americas LP, Strs Ohio, Vident Investment Advisory LLC, Vident Investment Advisory LLC, First Trust Advisors LP, Exane Derivatives, Actinver Wealth Management Inc., and Assenagon Asset Management S.A..

How do I buy shares of Qiagen?

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Qiagen's stock price today?

One share of QGEN stock can currently be purchased for approximately $48.93.

How big of a company is Qiagen?

Qiagen has a market capitalization of $11.14 billion and generates $1.53 billion in revenue each year. The company earns $-41,460,000.00 in net income (profit) each year or $1.43 on an earnings per share basis. Qiagen employs 5,096 workers across the globe.

What is Qiagen's official website?

The official website for Qiagen is www.qiagen.com.

How can I contact Qiagen?

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912. The company can be reached via phone at 31-77-355-6600 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.